Catalent to expand Madison plant
Catalent Inc., a Somerset N.J.-based pharma and consumer health corporation, will invest $200 million to expand biologics manufacturing sites in Madison and Bloomington, Indiana, the company announced. The investment, designed to meet projected growth among existing and future customers, will be phased as part of a three-year program.
Catalent says cell culture capacity will be increased at its Madison facility at 726 Heartland Trail, providing additional clinical and commercial production capacity. The work, which will more than double Catalent’s commercial biomanufacturing capacity and could add more than 100 employees here, is expected to be completed by mid-2021.